Tumour molecular profiling for deciding therapy-the French initiative

Nature Reviews Clinical Oncology

Volumn 9, Issue 8, 2012, Pages 479-486

  Nowak, Frédérique ^a   Soria, Jean Charles ^b   Calvo, Fabien ^a  

^a INSTITUT NATIONAL DU CANCER   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; CRIZOTINIB; DACARBAZINE; DASATINIB; ERLOTINIB; GEFITINIB; IMATINIB; LAPATINIB; NILOTINIB; PANITUMUMAB; TRASTUZUMAB; VEMURAFENIB;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADVANCED CANCER; BCR ABL GENE; BREAST CANCER; CANCER GENETICS; CANCER PATIENT; CANCER SURVIVAL; CANCER THERAPY; CHRONIC MYELOID LEUKEMIA; CLINICAL PRACTICE; COLORECTAL CANCER; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC TEST; DRUG COST; EGFR GENE; FRANCE; GASTROINTESTINAL STROMAL TUMOR; GENE; GENETIC SCREENING; HEALTH CARE ACCESS; HEALTH CARE DISPARITY; HEALTH CARE FACILITY; HEALTH CARE PLANNING; HEALTH CARE SYSTEM; HEALTH PROGRAM; HEALTH PROMOTION; HUMAN; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LUNG NON SMALL CELL CANCER; MEDICAL DECISION MAKING; MELANOMA; MINIMAL RESIDUAL DISEASE; MOLECULAR BIOLOGY; MOLECULAR DIAGNOSIS; MOLECULAR GENETICS; NATIONAL HEALTH ORGANIZATION; ONCOGENE K RAS; OVERALL SURVIVAL; PREDICTION; PRESCRIPTION; PRIORITY JOURNAL; PROGNOSIS; PROGRAM DEVELOPMENT; PROGRESSION FREE SURVIVAL; PUBLIC HEALTH SERVICE; REVIEW; STOMACH CANCER;

FRANCE; GENE EXPRESSION PROFILING; GOVERNMENT PROGRAMS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84864450130     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2012.42     Document Type: Review

References (56)

1. Torkamani, A., Verkhivker, G. & Schork, N. J. Cancer driver mutations in protein kinase genes. Cancer Lett. 281, 117-127 (2009).
2. Hochhaus, A. et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 23, 1054-1061 (2009).
3. Blanke, C. D. et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J. Clin. Oncol. 26, 626-632 (2008). (Pubitemid 351264358)
4. Verweij, J. et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: Randomised trial. Lancet 364, 1127-1134 (2004). (Pubitemid 39296599)
5. Bang, Y. J. et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet 376, 687-697 (2010).
6. Douillard, J. Y. et al., Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: Data from the randomized phase III INTEREST trial. J. Clin. Oncol. 28, 744-752 (2010).
7. Mok, T. S. et al. Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer. J. Clin. Oncol. 27, 5080-5087 (2009).
8. Piccart-Gebhart, M. J. et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 353, 1659-1672 (2005). (Pubitemid 41464705)
9. Van Cutsem, E. et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med. 360, 1408-1417 (2009).
10. Van Cutsem, E. et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: Updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J. Clin. Oncol. 29, 2011-2019 (2011).
11. Vogel, C. L. et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 20, 719-726 (2002). (Pubitemid 34111379)
12. European Medicines Agency [online], http://www.ema.europa.eu/ema/index. jsp?curl=pages/medicines/landing/epar-search.jsp&mid=WC0b01ac058001d124 (2012).
13. Blanchon, F. et al. Epidemiologic of primary bronchial carcinoma management in the general French hospital centers [French]. Rev. Mal. Respir. 19, 727-734 (2002). (Pubitemid 36019711)
14. Grivaux, M. et al. Five year survival for lung cancer patients managed in general hospitals [French]. Rev. Mal. Respir. 26, 37-44 (2009).
15. Étude des Registres de Cancers du Réseau Francim. Survie des patients atteints de cancer en France [French]. (Springer, Paris, 2007).
16. Institut de Veille Sanitaire. Projections de L'incidence et de la Mortalité par Cancer en France en 2011. Rapport technique [French]. (Saint Maurice, 2011).
17. European Commission. Enterprise and Industry: CE marking [online], http://ec.europa.eu/enterprise/policies/single-market-goods/cemarking/ (2012).
18. European Commission. DG Health & Consumers: Medical devices [online], http://ec.europa.eu/health/medical-devices/ (2012)
19. Moelans, C. B., de Weger, R. A. Van der Wall, E. & van Diest, P. J. Current technologies for HER2 testing in breast cancer. Crit. Rev. Oncol. Hematol. 80, 380-392 (2011).
20. Tsiatis, A. C. et al. Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: Diagnostic and clinical implications. J. Mol. Diagn. 12, 425-432 (2010).
21. Ma, E. S., Wong, C. L., Law, F. B., Chan, W. K. & Siu, D. Detection of KRAS mutations in colorectal cancer by high-resolution melting analysis. J. Clin. Pathol. 62, 886-891 (2009).
22. Magnin, S. et al. A multiplex SNaPshot assay as a rapid method for detecting KRAS and BRAF mutations in advanced colorectal cancers. J. Mol. Diagn. 13, 485-492 (2011).
23. Sundström, M. et al. KRAS analysis in colorectal carcinoma: Analytical aspects of Pyrosequencing and allele-specific PCR in clinical practice. BMC Cancer 10, 660 (2010).
24. Amado, R. G. et al. Wild-Type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol. 26, 1626-1634 (2008).
25. Karapetis, C. S. et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 359, 1757-1765 (2008).
26. Sharma, S. V., Bell, D. W., Settleman, J. & Haber, D. A. Epidermal growth factor receptor mutations in lung cancer. Nat. Rev. Cancer 7, 169-181 (2007).
27. Kancha, R. K., Peschel, C. & Duyster, J. The epidermal growth factor receptor-L861Q mutation increases kinase activity without leading to enhanced sensitivity toward epidermal growth factor receptor kinase inhibitors. J. Thorac. Oncol. 6, 387-392 (2011).
28. Loupakis, F. et al. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-Type metastatic colorectal cancer. Br. J. Cancer 101, 715-721 (2009).
29. Rouleau, E. et al. KRAS mutation status in colorectal cancer to predict response to EGFR targeted therapies: The need for a more precise definition. Br. J. Cancer 99, 2100 (2008).
30. Yasuda, H., Kobayashi, S. & Costa, D. B. EGFR exon 20 insertion mutations in non-small-cell lung cancer: Preclinical data and clinical implications. Lancet Oncol. 13, e23-31 (2011).
31. Zhou, Q. et al. Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer. J. Clin. Oncol. 29, 3316-3321 (2011).
32. Gow, C. H. et al. Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer. Ann. Oncol. 20, 696-702 (2009).
33. Park, S. et al. Discordance of molecular biomarkers associated with epidermal growth factor receptor pathway between primary tumors and lymph node metastasis in non-small cell lung cancer. J. Thorac. Oncol. 4, 809-815 (2009).
34. Sun, L. et al. Comparison of KRAS and EGFR gene status between primary non-small cell lung cancer and local lymph node metastases: Implications for clinical practice. J. Exp. Clin. Cancer Res. 30, 30 (2011).
35. Chapman, P. B. et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507-2516 (2011).
36. Kwak, E. L. et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 363, 1693-1703 (2010).
37. Pao, W. & Girard, N. New driver mutations in non-small-cell lung cancer. Lancet Oncol. 12, 175-180 (2011).
38. Institut National du Cancer. Découvrez le site du Plan cancer 2009-2013. [French] http://www.e-cancer.fr/plancancer-2009-2013 (2012).
39. Contre le Cancer. La réponse de François Hollande à la ligue Contre le Cancer. http://www.ligue-cancer.net/article/8934-la-reponse- de-francois-hollande-A-la-ligue-contre-le-cancer (2012).
40. Intergroupe Francophone de Cancérologie Thoracique. Biomarqueurs France [online], http://www.ifct.fr/v3/index.php?option=com- flexicontent&view=items&cid=267&id=1827&itemid=652 (2012).
41. Jabbour, E. et al. Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia. Cancer 117, 1800-1811 (2011).
42. Institut National du Cancer. Cancer du Poumon-Bilan Initial [French] (Boulogne-Billancourt, 2011).
43. Rosell, R. et al. Screening for epidermal growth factor receptor mutations in lung cancer. N. Engl. J. Med. 361, 958-967 (2009).
44. Sekine, I., Yamamoto, N., Nishio, K. & Saijo, N. Emerging ethnic differences in lung cancer therapy. Br. J. Cancer 99, 1757-1762 (2008).
45. Elkin, E. B. et al. HER-2 testing and trastuzumab therapy for metastatic breast cancer: A cost-effectiveness analysis. J. Clin. Oncol. 22, 854-863 (2004). (Pubitemid 41103597)
46. Blank, P. R., Moch, H., Szucs, T. D. & Schwenkglenks, M. KRAS and BRAF mutation analysis in metastatic colorectal cancer: A cost-effectiveness analysis from a Swiss perspective. Clin. Cancer Res. 17, 6338-6346 (2011).
47. Mancl, E. E., Kolesar, J. M. & Vermeulen, L. C. Clinical and economic value of screening for Kras mutations as predictors of response to epidermal growth factor receptor inhibitors. Am. J. Health Syst. Pharm. 66, 2105-2112 (2009).
48. Borget, I. et al. Comparative cost-effectiveness of three strategies for guiding second-line erlotinib initiation in non small-cell lung cancer: A French prospective multicenter study (ERMETIC Project Part 3). Eur. Respir. J. 39, 172-179 (2012).
49. de Lima Lopes, G. Jr et al. Cost-effectiveness of epidermal growth factor receptor mutation testing and first-line treatment with gefitinib for patients with advanced adenocarcinoma of the lung. Cancer 118, 1032-1039 (2011).
50. Cancer Research UK. Stratified medicine programme [online], http://science.cancerresearchuk.org/research/how-we-deliver-our-research/others/ by-programme/stratified-medicine-programme/ (2012).
51. Andre, F. et al. Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array. Clin. Cancer Res. 15, 441-451 (2009).
52. Gong, Y. et al. Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: A gene-expression profiling study. Lancet Oncol. 8, 203-211 (2007).
53. Lipson, D. et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. PLoS ONE 4, e7887 (2009).
54. Cronin, M. & Ross, J. S. Comprehensive next-generation cancer genome sequencing in the era of targeted therapy and personalized oncology. Biomark. Med. 5, 293-305 (2011).
55. Jones, S. J. et al. Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitors. Genome Biol. 11, R82 (2010).
56. Ley, T. J. et al. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature 456, 66-72 (2008).